ASX Release

4 November 2026

RESULTS OF ANNUAL GENERAL MEETING

MELBOURNE, AUSTRALIA 4 November 2026: Arovella Therapeutics, (ASX: ALA), advises that nine out of ten resolutions considered at the Annual General Meeting held today were carried by poll.

In accordance with ASX Listing rule 3.13.2 and Section 251AA of the Corporations Act 2001, details of the proxies received, and votes cast in respect of each resolution are attached.

Yours faithfully

Lachlan Mallia
Company Secretary
Arovella Therapeutics Ltd
investor@arovella.com

About Arovella Therapeutics Ltd

Arovella Therapeutics Ltd (ASX: ALA) is focused on developing its invariant natural killer T (iNKT) cell therapy platform licensed from Imperial College London to treat blood cancers, solid tumours, and autoimmune disease. Arovella's lead product is ALA-101. ALA-101 consists of CAR19-iNKT cells that have been modified to produce a Chimeric Antigen Receptor (CAR) that targets CD19. CD19 is an antigen found on the surface of numerous cancer types. iNKT cells also contain an invariant T cell receptor (iTCR) that targets glycolipid bound CD1d, another antigen found on the surface of several cancer types. ALA-101 has had its Investigational New Drug application (IND) accepted by the US FDA and is being developed as an allogeneic cell therapy, which means it can be given from a healthy donor to a patient. Arovella is also expanding into solid tumour treatment through its CLDN18.2-targeting technology licensed from Sparx Group. Arovella will also incorporate its IL-12-TM technology into its solid tumour programs.

For more information, visit www.arovella.com

Results of Meeting

Arovella Therapeutics Limited

Annual General Meeting

Wednesday, 04 November 2026

Automic
GPO Box 5193, Sydney, NSW 2001
P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)
F +61 (0)2 8583 3040 E hello@automic.com.au
ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
1 Adoption of Remuneration Report	P	155,460,096 98.32%	2,159,185 1.37%	630,890	496,466 0.31%	167,904,656 98.33%	2,843,845 1.67%	1,161,751	-
2 Election of David Williams as a Director	P	157,337,830 99.00%	1,251,152 0.79%	12,300	345,355 0.22%	170,353,501 98.99%	1,744,451 1.01%	12,300	Carried
3 Election of Mark Diamond as a Director	P	154,667,776 97.63%	3,410,706 2.15%	522,800	345,355 0.22%	167,844,362 97.72%	3,910,706 2.28%	355,184	Carried
4 Election of Michael Thurn as a Director	P	154,717,686 97.66%	3,360,796 2.12%	522,800	345,355 0.22%	167,894,272 97.75%	3,860,796 2.25%	355,184	Carried
5 Approval for Issue of Performance Rights to David Williams under the LTIP	P	152,157,641 95.97%	6,036,530 3.81%	207,111	345,355 0.22%	164,642,451 96.29%	6,338,468 3.71%	929,333	Carried
6 Amendment to constitution	P	153,986,457 97.35%	3,483,301 2.20%	571,410	705,469 0.45%	167,273,157 97.96%	3,483,301 2.04%	1,153,794	Carried
7 Renewal of proportional takeover provisions in the Company's Constitution	P	155,901,347 98.34%	1,933,821 1.22%	406,000	705,469 0.44%	169,188,047 98.58%	2,433,821 1.42%	488,384	Carried
8 Renewal of shareholder approval for the LTIP	P	153,957,803 97.13%	3,887,497 2.45%	178,300	655,469 0.41%	166,256,760 97.43%	4,380,796 2.57%	982,906	Carried
9 Ratification of prior issue of Options	P	37,490,460 23.64%	120,388,408 75.91%	362,300	705,469 0.44%	47,696,056 27.85%	123,551,896 72.15%	862,300	Not Carried

		Proxy Votes (as at proxy voting close)				Poll Results (if applicable)			Results
Resolution	**Decided by Show of Hands (S) or Poll (P)**	**FOR**	**AGAINST**	**ABSTAIN**	**PROXY'S DISCRETION**	**FOR**	**AGAINST**	**ABSTAIN**	**OUTCOME**
10 Approval of additional 10% Placement Capacity	P	155,835,166 98.29%	2,151,113 1.36%	406,000	554,358 0.35%	168,977,456 98.46%	2,644,412 1.54%	488,384	Carried